These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9861551)

  • 1. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate.
    Kollins SH; Rush CR; Pazzaglia PJ; Ali JA
    Exp Clin Psychopharmacol; 1998 Nov; 6(4):367-74. PubMed ID: 9861551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulant-induced changes in smoking and caloric intake: influence of rate of onset.
    Vansickel AR; Poole MM; Stoops WW; Hays KE; Upchurch MB; Glaser PE; Rush CR
    Pharmacol Biochem Behav; 2009 Jun; 92(4):597-602. PubMed ID: 19281837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers.
    Rush CR; Baker RW
    Exp Clin Psychopharmacol; 2001 Feb; 9(1):59-73. PubMed ID: 11519636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
    Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
    J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans: a dose-response analysis.
    Stoops WW; Glaser PE; Rush CR
    Drug Alcohol Depend; 2003 Aug; 71(2):179-86. PubMed ID: 12927656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans.
    Stoops WW; Glaser PE; Fillmore MT; Rush CR
    J Psychopharmacol; 2004 Dec; 18(4):534-43. PubMed ID: 15582920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute behavioral and physiological effects of modafinil in drug abusers.
    Rush CR; Kelly TH; Hays LR; Baker RW; Wooten AF
    Behav Pharmacol; 2002 Mar; 13(2):105-15. PubMed ID: 11981223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment.
    Roache JD; Grabowski J; Schmitz JM; Creson DL; Rhoades HM
    J Clin Psychopharmacol; 2000 Feb; 20(1):61-8. PubMed ID: 10653210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential.
    Spencer TJ; Biederman J; Martin JM; Moorehead TM; Mirto T; Clarke A; Batchelder H; Faraone SV
    Postgrad Med; 2012 Jan; 124(1):166-73. PubMed ID: 22314126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs.
    Lavy E; Prise U; Soldani G; Neri D; Brandriss N; Bar Chaim A; Giorgi M
    Vet J; 2011 Sep; 189(3):336-40. PubMed ID: 20696604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinforcing effects of methylphenidate: influence of dose and behavioral demands following drug administration.
    Stoops WW; Lile JA; Fillmore MT; Glaser PE; Rush CR
    Psychopharmacology (Berl); 2005 Jan; 177(3):349-55. PubMed ID: 15609070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
    Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.
    Lile JA; Stoops WW; Durell TM; Glaser PE; Rush CR
    Exp Clin Psychopharmacol; 2006 May; 14(2):136-47. PubMed ID: 16756417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans.
    Sevak RJ; Stoops WW; Hays LR; Rush CR
    J Pharmacol Exp Ther; 2009 Mar; 328(3):1007-18. PubMed ID: 19104030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
    Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
    Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
    Heal DJ; Pierce DM
    CNS Drugs; 2006; 20(9):713-38. PubMed ID: 16953648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.